What is the prevalence of Triosephosphate Isomerase Deficiency?
How many people does Triosephosphate Isomerase Deficiency affect? Does it have the same prevalence in men and women? And in the different countries?
Triosephosphate Isomerase Deficiency is an extremely rare autosomal recessive disorder characterized by a deficiency of the enzyme triosephosphate isomerase. It is estimated to affect less than 1 in 100,000 individuals worldwide. The condition is more commonly found in individuals of Amish descent, with a prevalence of approximately 1 in 4,000 in this population. Triosephosphate isomerase deficiency can lead to a variety of symptoms, including neurological abnormalities, muscle weakness, and hemolytic anemia. Early diagnosis and management are crucial for individuals affected by this condition.
Triosephosphate Isomerase Deficiency (TPI deficiency) is an extremely rare autosomal recessive disorder characterized by a deficiency of the enzyme triosephosphate isomerase. This enzyme plays a crucial role in the glycolytic pathway, which is responsible for the breakdown of glucose for energy production. TPI deficiency is caused by mutations in the TPI1 gene.
The prevalence of TPI deficiency is exceptionally low, with only a few dozen cases reported worldwide. It is estimated to affect approximately 1 in every 2 million individuals. The disorder has been documented in various ethnic groups, suggesting no specific racial or ethnic predisposition.
TPI deficiency typically manifests in early childhood and can present with a wide range of symptoms, including neurological abnormalities, muscle weakness, developmental delay, and hemolytic anemia. The severity of the condition can vary, with some individuals experiencing mild symptoms while others may have a more severe and rapidly progressive form of the disease.
Due to its rarity, TPI deficiency is often challenging to diagnose, and treatment options are limited. Supportive care, including physical and occupational therapy, may help manage symptoms and improve quality of life for affected individuals.
